A couple of ARK Invest exchange-traded funds run by ETF star Cathie Wood made a huge buy on Wednesday. Specifically, these funds bought roughly $87 million worth of Ginkgo Bioworks Holdings Inc. (NYSE: DNA), as the prices of these funds were very mixed on Wednesday. Note though that they are up a fair amount in the past year.
ARK Genomic Revolution ETF (NYSEARCA: ARKG) bought 1,525,065 shares of Ginkgo, and ARK Innovation ETF (NYSEARCA: ARKK) bought 6,739,168 shares. At Wednesday’s closing prices, this would have valued the sales at roughly $87.5 million altogether. Even though this is a small fraction of their total holdings, every little bit counts. The Genomic Revolution ETF is up less than 8% and the other is up 17% in the past year.
Check out all the ARK Invest purchases for Wednesday as well:
|ARKG||DYNS||DYNAMICS SPECIAL PURPOSE||600|
|ARKK||PACB||PACIFIC BIOSCIENCES OF CALIFORNIA||57,511|
|ARKQ||BLDE||BLADE AIR MOBILITY||148,623|
|ARKX||PRNT||3D PRINTING ETF||1,022|
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St., owner of 247wallst.com.
Sponsored: Find a Qualified Financial Advisor:
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.